{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:31:30Z","timestamp":1793745090932,"version":"4.6.1"},"reference-count":81,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals plc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Takeda Pharmaceuticals U.S.A., Inc"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.bbmt.2015.09.024","type":"journal-article","created":{"date-parts":[[2015,10,25]],"date-time":"2015-10-25T15:50:11Z","timestamp":1445788211000},"page":"400-409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":256,"title":["Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment"],"prefix":"10.1016","volume":"22","author":[{"given":"Jean-Hugues","family":"Dalle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-5053","authenticated-orcid":false,"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2015.09.024_bib1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome","volume":"16","author":"Coppell","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib2","first-page":"5","article-title":"Fatal veno-occlusive disease of the liver after chemotherapy, whole body irradiation and bone marrow transplantation for refractory acute leukemia","volume":"55","author":"Jacobs","year":"1979","journal-title":"S\u00a0Afr Med J"},{"key":"10.1016\/j.bbmt.2015.09.024_bib3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.bmt.1704069","article-title":"Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients","volume":"32","author":"Barker","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.1840040121","article-title":"Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors","volume":"4","author":"McDonald","year":"1984","journal-title":"Hepatology"},{"key":"10.1016\/j.bbmt.2015.09.024_bib5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/sj.bmt.1705899","article-title":"Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies","volume":"41","author":"Ho","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib6","series-title":"The EBMT-ESH Handbook on Haemopoietic Stem Cell Transplantation (Chapter 11)","article-title":"Early complications after HSCT","author":"Carreras","year":"2012"},{"key":"10.1016\/j.bbmt.2015.09.024_bib7","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1097\/01.tp.0000183288.67746.44","article-title":"Diagnosis of hepatic veno-occlusive disease by plasminogen activator inhibitor-1 plasma antigen levels: a prospective analysis in 350 allogeneic hematopoietic stem cell recipients","volume":"80","author":"Pihusch","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2015.09.024_bib8","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.bbmt.2010.02.016","article-title":"Prediction of veno-occlusive disease using biomarkers of endothelial injury","volume":"16","author":"Cutler","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1586\/ehm.12.18","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation","volume":"5","author":"Corbacioglu","year":"2012","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.bbmt.2015.09.024_bib10","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/bmt.2014.168","article-title":"Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen","volume":"49","author":"Tsirigotis","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib11","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/sj.bmt.1705835","article-title":"Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation","volume":"40","author":"Cheuk","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib12","first-page":"1396","article-title":"A\u00a0prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation","volume":"90","author":"Cesaro","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2015.09.024_bib13","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005","article-title":"The syndrome of hepatic veno-occlusive disease after marrow transplantation","volume":"85","author":"Bearman","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.024_bib14","first-page":"3599","volume":"92","author":"Carreras","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.024_bib15","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s12185-014-1578-y","article-title":"Experience from a single paediatric transplant centre with identification of some protective and risk factors concerning the development of hepatic veno-occlusive disease in children after allogeneic hematopoietic stem cell transplant","volume":"99","author":"Maximova","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2015.09.024_bib16","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.3816\/CLM.2002.s.007","article-title":"Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg\u00ae)","volume":"2","author":"McDonald","year":"2002","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.bbmt.2015.09.024_bib17","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","article-title":"Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation","volume":"102","author":"Wadleigh","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.024_bib18","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1182\/blood.V92.12.4568","article-title":"Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation","volume":"92","author":"H\u00e4gglund","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.024_bib19","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1182\/blood-2014-03-551630","article-title":"How I treat sinusoidal obstruction syndrome","volume":"123","author":"Chao","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.024_bib20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0301-472X(03)00070-5","article-title":"Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation","volume":"31","author":"Moscard\u00f3","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2015.09.024_bib21","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.bmt.1702854","article-title":"Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin","volume":"27","author":"Simon","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib22","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/sj.bmt.1704943","article-title":"The hemochromatosis C282Y allele: a risk factor for hepatic veno-occlusive disease after hematopoietic stem cell transplantation","volume":"35","author":"Kallianpur","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib23","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/bmt.2014.16","article-title":"MTHFR C677T\/A1298C genotype: a possible risk factor for liver sinusoidal obstruction syndrome","volume":"49","author":"Efrati","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib24","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood-2003-11-3778","article-title":"Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation","volume":"104","author":"Srivastava","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.024_bib25","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/sj.bmt.1701225","article-title":"Association of pulmonary function testing abnormalities and severe veno-occlusive disease of the liver after marrow transplantation","volume":"21","author":"Matute-Bello","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2015.09.024_bib27","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/10245332.1999.11746478","article-title":"BMT: serum ferritin as risk factor for veno-occlusive disease of the liver. Prospective cohort study","volume":"4","author":"Morado","year":"2000","journal-title":"Hematology"},{"key":"10.1016\/j.bbmt.2015.09.024_bib28","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/sj.bmt.1701506","article-title":"Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors","volume":"22","author":"Hasegawa","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib29","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.bbmt.2011.06.006","article-title":"The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade","volume":"17","author":"Carreras","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib30","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3324\/haematol.2014.105197","article-title":"Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"99","author":"Nagler","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2015.09.024_bib31","first-page":"109","article-title":"Hepatic veno-occlusive disease following haematopoietic cell transplantation: pathogenesis, diagnosis, risk factors, prophylaxis and treatment VOD following cell transplantation","volume":"3","author":"Carreras","year":"2013","journal-title":"Hematology"},{"key":"10.1016\/j.bbmt.2015.09.024_bib32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/ehm.09.30","article-title":"Use of defibrotide in the treatment and prevention of veno-occlusive disease","volume":"2","author":"Richardson","year":"2009","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.bbmt.2015.09.024_bib33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.bmt.1701068","article-title":"Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver","volume":"21","author":"Fisher","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib34","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bjh.12558","article-title":"BCSH\/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation","volume":"163","author":"Dignan","year":"2013","journal-title":"Br J\u00a0Haematol"},{"key":"10.1016\/j.bbmt.2015.09.024_bib35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2036.2006.02742.x","article-title":"Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome","volume":"23","author":"Helmy","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bbmt.2015.09.024_bib36","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.bmt.1705485","article-title":"Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide","volume":"38","author":"Corbacioglu","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib37","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2002-04-1216","article-title":"Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.024_bib38","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11060-014-1576-1","article-title":"Toxicity of tandem high-dose chemotherapy and autologous stem cell transplantation using carboplatin-thiotepa-etoposide and cyclophosphamide-melphalan regimens for malignant brain tumors in children and young adults","volume":"120","author":"Lee","year":"2014","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.bbmt.2015.09.024_bib39","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/bbmt.2002.v8.pm12374454","volume":"8","author":"Kashyap","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib40","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000028359","article-title":"Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes","volume":"60","author":"DeLeve","year":"2000","journal-title":"Pharmacology"},{"key":"10.1016\/j.bbmt.2015.09.024_bib41","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/pds.1504","article-title":"Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics","volume":"17","author":"Brice","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.bbmt.2015.09.024_bib42","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2003-04-1311","article-title":"Hepatic injury after non myeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients","volume":"103","author":"Hogan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.024_bib43","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2015.09.024_bib44","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/bjh.13215","article-title":"How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation","volume":"168","author":"Carreras","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2015.09.024_bib45","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2015.09.024_bib46","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","article-title":"Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial","volume":"379","author":"Corbacioglu","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2015.09.024_bib47","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.bbmt.2014.09.026","article-title":"Veno-occlusive disease of the liver in the absence of elevation in bilirubin in pediatric patients after hematopoietic stem cell transplant","volume":"21","author":"Myers","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib48","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00007890-200207150-00011","article-title":"Prognostic value of Doppler-ultrasonography in hepatic veno-occlusive disease","volume":"74","author":"Lassau","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2015.09.024_bib49","doi-asserted-by":"crossref","first-page":"831","DOI":"10.2169\/internalmedicine.48.1404","article-title":"Early ultrasonographic diagnosis and clinical follow-up of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in a patient with acute lymphoblastic leukemia","volume":"48","author":"Matsumoto","year":"2009","journal-title":"Intern Med"},{"key":"10.1016\/j.bbmt.2015.09.024_bib50","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1148\/radiology.184.3.1509050","article-title":"Venocclusive disease of the liver: prospective study of US evaluation","volume":"184","author":"Hommeyer","year":"1992","journal-title":"Radiology"},{"key":"10.1016\/j.bbmt.2015.09.024_bib51","first-page":"685","article-title":"Association of hepatic veno-occlusive disease with interstitial pneumonitis in bone marrow transplant recipients","volume":"4","author":"Wingard","year":"1989","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib52","doi-asserted-by":"crossref","first-page":"589","DOI":"10.4065\/78.5.589","article-title":"Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation","volume":"78","author":"Kumar","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.bbmt.2015.09.024_bib53","first-page":"185","article-title":"Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation","volume":"18","author":"Rosenthal","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib54","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/00043426-200212000-00013","article-title":"Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients","volume":"24","author":"Reiss","year":"2002","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.bbmt.2015.09.024_bib55","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-0609.1991.tb01859.x","article-title":"Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation","volume":"47","author":"Marsa-Vila","year":"1991","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2015.09.024_bib56","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/sj.bmt.1703342","article-title":"A\u00a0randomized trial of heparin plus ursodiol heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation","volume":"29","author":"Park","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib57","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3346\/jkms.2006.21.5.897","article-title":"Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children","volume":"21","author":"Song","year":"2006","journal-title":"J\u00a0Korean Med Sci"},{"key":"10.1016\/j.bbmt.2015.09.024_bib58","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/sj.bmt.1705297","article-title":"Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients\u00a0undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"37","author":"Imran","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib59","doi-asserted-by":"crossref","first-page":"975","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00002","article-title":"Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial","volume":"128","author":"Essell","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2015.09.024_bib60","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.0.CO;2-N","article-title":"The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation","volume":"64","author":"Ohashi","year":"2000","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2015.09.024_bib61","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.bbmt.2006.09.012","article-title":"Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation","volume":"13","author":"Tay","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib62","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1345\/aph.1D235","article-title":"Anti-thrombin III in the management of hematopoietic stem-cell transplantation-associated toxicity","volume":"38","author":"Ibrahim","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.bbmt.2015.09.024_bib63","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MBC.0b013e3282f2b5d9","article-title":"Early intervention with antithrombin III therapy to prevent progression of hepatic venoocclusive disease","volume":"19","author":"Peres","year":"2008","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.bbmt.2015.09.024_bib64","first-page":"795","article-title":"Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III\/defibrotide therapy","volume":"91","author":"Haussmann","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2015.09.024_bib65","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/oli.2006.16.105","article-title":"Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action","volume":"16","author":"Kornblum","year":"2006","journal-title":"Oligonucleotides"},{"key":"10.1016\/j.bbmt.2015.09.024_bib66","unstructured":"Defitelio Summary of Product Characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002393\/WC500153150.pdf. Accessed May 13, 2015."},{"key":"10.1016\/j.bbmt.2015.09.024_bib67","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1182\/blood.V114.22.654.654","article-title":"Defibrotide (DF) in the treatment of severe hepatic veno-occlusive disease (VOD) with multi-organ failure (MOF) following stem cell transplantation (SCT): results of a phase 3 study utilizing a historical control","volume":"114","author":"Richardson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.024_bib68","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood.V116.21.3481.3481","article-title":"Meta-analysis of defibrotide (DF) in the treatment of severe hepatic veno-occlusive disease (VOD) with multi-organ failure (MOF) with comparison to a historical control (HC)","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.024_bib69","first-page":"S74","article-title":"Defibrotide for pediatric and adult patients with hepatic veno-occlusive disease: interim age subgroup survival analysis from an ongoing expanded access program in the US","volume":"50","author":"Richardson","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib70","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.bbmt.2014.11.135","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease: an update from the international compassionate use program in 710 patients","volume":"21","author":"Corbacioglu","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib71","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.bmt.1705896","article-title":"Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone","volume":"41","author":"Al Beihany","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib72","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.bbmt.2012.11.011","article-title":"High-dose methylprednisolone for veno-occlusive disease of the liver in pediatric hematopoietic stem cell transplantation recipients","volume":"19","author":"Myers","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib73","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1080\/1042819021000032962","article-title":"Veno-occlusive disease of the liver after blood and marrow transplantation: analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activator","volume":"43","author":"Litzow","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2015.09.024_bib74","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/sj.bmt.1703881","article-title":"Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: effectiveness and a scoring system for initiating treatment","volume":"31","author":"Bajwa","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib75","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood.V89.5.1501","article-title":"Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients","volume":"89","author":"Bearman","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.024_bib76","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/bmt.2013.101","article-title":"Experiences of t-PA use in moderate-to-severe hepatic veno-occlusive disease after hematopoietic SCT: is it still reasonable to use t-PA?","volume":"48","author":"Yoon","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib77","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000046590","article-title":"Hepatic veno-occlusive disease following hematopoietic stem cell transplantation","volume":"106","author":"Richardson","year":"2001","journal-title":"Acta Haematol"},{"key":"10.1016\/j.bbmt.2015.09.024_bib78","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1200\/JCO.1993.11.9.1729","article-title":"Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation","volume":"11","author":"Bearman","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.09.024_bib79","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.bbmt.2007.08.002","article-title":"Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients","volume":"13","author":"Carreras","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib80","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.bmt.1704329","article-title":"Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention","volume":"33","author":"Corbacioglu","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.024_bib81","first-page":"700","volume":"122","author":"Richardson","year":"2013","journal-title":"Blood (ASH annual meeting abstracts)"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115006497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115006497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:53:45Z","timestamp":1761058425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879115006497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S1083879115006497"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.024","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}